Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | DRD3 | P35462 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | DRD1 | P21728 | 1/20 | 0.95 |
| ▸ | ACHE | P22303 | 1/20 | 0.95 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.95 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | HTR2B | P41595 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | HTR3B | O95264 | 1/20 | 0.71 |
| ▸ | MPO | P05164 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | DRD4 | P21917 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromopride SCHEMBL18338829 | 1.00 | ADRA2A (0.95) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Bromopride SCHEMBL8385045 | 0.99 | ADRA2A (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Bromopride SCHEMBL54497 | 0.98 | ADRA2A (1.00) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Bromopride SCHEMBL1648933 | 0.95 | ADRA2A (0.95) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL6569231 | 0.86 | RAB9A (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL6263013 | 0.86 | RAB9A (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL18614363 | 0.86 | RAB9A (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL5012583 | 0.86 | RAB9A (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL133509 | 0.86 | RAB9A (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL205200 | 0.85 | RAB9A (1.00) | ADRA2ACYP2D6DRD3CYP1A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019018-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Chase Pharmaceuticals Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20200253893-A1 | MEMANTINE COMBINATIONS AND USE | CHASE PHARMACEUTICALS CORP (US) | 2020-08-13 | — | — | US | disclosed |
| US-10548855-B2 | Memantine combinations and use | CHASE PHARMACEUTICALS CORPORATION (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190269627-A1 | MEMANTINE COMBINATIONS AND USE | CHASE PHARMACEUTICALS CORP (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3532060-A1 | MEMANTINE COMBINATIONS AND USE | Chase Pharmaceuticals Corporation (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180250270-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3347012-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Chase Pharmaceuticals Corporation (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3347011-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Chase Pharmaceuticals Corporation (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2018081508-A1 | MEMANTINE COMBINATIONS AND USE | CHASE PHARMACEUTICAL CORPORATION (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180116979-A1 | MEMANTINE COMBINATIONS AND USE | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2018039159-A1 | MUSCARINIC M2-ANTAGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017044714-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044693-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | DRD2 130/4885ADRA2A 59/4885CYP2D6 765/4885 |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHRM3, CHRM2, CHRM4 | DRD2 130/4885ADRA2A 59/4885CYP2D6 765/4885 |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | DRD2 130/4885ADRA2A 59/4885CYP2D6 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.